Dockside LLC Acquires New Shares in Ralliant Corporation $RAL

Dockside LLC acquired a new stake in shares of Ralliant Corporation (NYSE:RAL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 36,246 shares of the company’s stock, valued at approximately $1,845,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Ralliant by 10.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after buying an additional 1,415,327 shares in the last quarter. Dodge & Cox raised its stake in shares of Ralliant by 13.3% in the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after buying an additional 1,434,376 shares in the last quarter. Viking Global Investors LP bought a new stake in shares of Ralliant in the 2nd quarter worth $257,200,000. State Street Corp bought a new stake in shares of Ralliant in the 2nd quarter worth $213,096,000. Finally, Invesco Ltd. raised its stake in shares of Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock worth $169,309,000 after buying an additional 1,835,128 shares in the last quarter.

Ralliant Stock Performance

Shares of RAL stock opened at $66.00 on Friday. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $67.01. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $7.39 billion and a price-to-earnings ratio of -6.03. The stock’s fifty day simple moving average is $53.04 and its 200-day simple moving average is $49.83.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million for the quarter. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s payout ratio is currently -1.83%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on RAL shares. Evercore started coverage on Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price on the stock. Barclays lifted their target price on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Royal Bank Of Canada lifted their target price on Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Oppenheimer lifted their target price on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Finally, Morgan Stanley lifted their target price on Ralliant from $45.00 to $68.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $67.30.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.